{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:48:40Z","timestamp":1790419720163,"version":"4.1.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1038\/nrrheum.2014.104","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T08:41:44Z","timestamp":1404204104000},"page":"484-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Key advances in the clinical approach to ANCA-associated vasculitis"],"prefix":"10.1038","volume":"10","author":[{"given":"Cees G. M.","family":"Kallenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,1]]},"reference":[{"key":"BFnrrheum2014104_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/art.1780330802","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder, G. G. et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum. 33, 1065\u20131067 (1990).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/art.1780330812","volume":"33","author":"JF Fries","year":"1990","unstructured":"Fries, J. F. et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 33, 1135\u20131136 (1990).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"JC Jennette","year":"1994","unstructured":"Jennette, J. C. et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37, 187\u2013192 (1994).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts, R. et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann. Rheum. Dis. 66, 222\u2013227 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/rheumatology\/ken079","volume":"47","author":"LJ Liu","year":"2008","unstructured":"Liu, L. J., Chen, M., Yu, F., Zhao, M. H. & Wang, H. Y. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology 47, 708\u2013712 (2008).","journal-title":"Rheumatology"},{"key":"BFnrrheum2014104_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10067-011-1793-3","volume":"31","author":"S Kamali","year":"2012","unstructured":"Kamali, S. et al. Re-evaluation of 129 patients with systemic necrotizing vasculitis by using classification algorithm according to consensus methodology. Clin. Rheumatol. 31, 325\u2013328 (2012).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum2014104_CR7","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3899\/jrheum.111352","volume":"39","author":"AG Uribe","year":"2012","unstructured":"Uribe, A. G. et al. Increased sensitivity of the European Medicines Agency algorithm for classification of childhood granulomatosis with polyangiitis. J. Rheumatol. 39, 1687\u20131697 (2012).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014104_CR8","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1136\/annrheumdis-2013-203511","volume":"72","author":"R Abdulkader","year":"2013","unstructured":"Abdulkader, R., Lane, S. E., Scott, D. G. & Watts, R. A. Classification of vasculitis: EMA classification using CHCC 2012 definitions. Ann. Rheum. Dis. 72, 1888 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette, J. C. et al. 2012 Revised international Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 65, 1\u201311 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons, P. A. et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214\u2013223 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2014104_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrneph.2009.67","volume":"5","author":"M Chen","year":"2009","unstructured":"Chen, M., Kallenberg, C. G. & Zhao M. H. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat. Rev. Nephrol. 5, 313\u2013318 (2009).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrrheum2014104_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1681\/ASN.2006091021","volume":"18","author":"M Chen","year":"2007","unstructured":"Chen, M. et al. Antineutrophil cytoplasmic autoantibody negative pauci-immune crescentic glomerulonephritis. J. Am.Soc. Nephrol. 18, 599\u2013605 (2007).","journal-title":"J. Am.Soc. Nephrol."},{"key":"BFnrrheum2014104_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1681\/ASN.2011090920","volume":"23","author":"R Kain","year":"2012","unstructured":"Kain, R. et al. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J. Am. Soc. Nephrol. 23, 556\u2013566 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014104_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1681\/ASN.2011030273","volume":"23","author":"AJ Roth","year":"2012","unstructured":"Roth, A. J. et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J. Am. Soc. Nephrol. 23, 545\u2013555 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014104_CR15","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1172\/JCI65292","volume":"123","author":"AJ Roth","year":"2013","unstructured":"Roth, A. J. et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J. Clin. Invest. 123, 1773\u20131783 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum2014104_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ndt\/gft416","volume":"29","author":"J Land","year":"2014","unstructured":"Land, J., Rutgers, A. & Kallenberg, C. G. Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody. Nephrol. Dial. Transplant. 29, 739\u2013745 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrrheum2014104_CR17","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/art.21250","volume":"52","author":"RA Sinico","year":"2005","unstructured":"Sinico, R. A. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 52, 2926\u20132935 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","volume":"143","author":"R Sabl\u00e9-Fourtassou","year":"2005","unstructured":"Sabl\u00e9-Fourtassou, R. et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann. Intern. Med. 143, 632\u2013638 (2005).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2014104_CR19","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/art.21253","volume":"52","author":"CG Kallenberg","year":"2005","unstructured":"Kallenberg, C. G. Churg-Strauss syndrome: just one disease entity? Arthritis Rheum. 52, 2589\u20132593 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR20","doi-asserted-by":"crossref","unstructured":"International study group for Beh\u00e7et's disease. Criteria for diagnosis of Beh\u00e7et's disease. Lancet 335, 1078\u20131080 (1990).","DOI":"10.1016\/0140-6736(90)92643-V"},{"key":"BFnrrheum2014104_CR21","first-page":"619","volume":"17","author":"A Craven","year":"2013","unstructured":"Craven, A. et al. ACR\/EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS). Clin. Exp. Immunol. 17, 619\u2013621 (2013).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum2014104_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneph.2013.225","volume":"10","author":"U Sch\u00f6nermarck","year":"2013","unstructured":"Sch\u00f6nermarck, U., Gross, W. L. & de Groot, K. Treatment of ANCA-associated vasculitis. Nat. Rev. Nephrol. 10, 25\u201336 (2013).","journal-title":"Nat. Rev. Nephrol."},{"issue":"1 Suppl. 70","key":"BFnrrheum2014104_CR23","first-page":"S22","volume":"30","author":"U Garske","year":"2012","unstructured":"Garske, U. et al. Intra- and inter-rater reliability of endonasal activity estimation in granulomatosis with polyangiitis (Wegener's). Clin. Exp. Rheumatol. 30, (1 Suppl. 70), S22\u2013S28 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2014104_CR24","first-page":"671","volume":"87","author":"RA Luqmani","year":"1994","unstructured":"Luqmani, R. A. et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87, 671\u2013678 (1994).","journal-title":"QJM"},{"key":"BFnrrheum2014104_CR25","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar, C. et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann. Rheum. Dis. 68, 1827\u20131832 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/rheumatology\/keq400","volume":"50","author":"R Suppiah","year":"2011","unstructured":"Suppiah, R. et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford) 50, 899\u2013905 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014104_CR27","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","volume":"44","author":"JH Stone","year":"2001","unstructured":"Stone, J. H. et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 44, 912\u2013920 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/art.23707","volume":"59","author":"AD Mahr","year":"2008","unstructured":"Mahr, A. D. et al. Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. Arthritis Rheum. 59, 884\u2013891 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488\u2013494 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR30","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1136\/annrheumdis-2012-202111","volume":"72","author":"P Dolezalova","year":"2013","unstructured":"Dolezalova, P. et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann. Rheum. Dis. 72, 1628\u20131633 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/art.1780400222","volume":"40","author":"AR Exley","year":"1997","unstructured":"Exley, A. R. et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 40, 371\u2013380 (1997).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich, B. et al. EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 66, 605\u2013617 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR33","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/ard.2007.071936","volume":"67","author":"C Mukhtyar","year":"2008","unstructured":"Mukhtyar, C. et al. Outcomes from studies of antineutrophil cytoplasm antibody-associated vasculitis: a systemic review by the European League Against Rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 67, 1004\u20131010 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR34","doi-asserted-by":"publisher","unstructured":"Robson, J. et al. Damage in ANCA-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann. Rheum. Dis. http:\/\/dx.doi.org\/10.1136\/annrheumdis-2013-203927 (2013).","DOI":"10.1136\/annrheumdis-2013-203927"},{"key":"BFnrrheum2014104_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/acr.20649","volume":"64","author":"G Tomasson","year":"2012","unstructured":"Tomasson, G. et al. Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res. 64, 273\u2013279 (2012).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum2014104_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/annrheumdis-2012-202750","volume":"73","author":"N Basu","year":"2013","unstructured":"Basu, N. et al. The characterization and determinants of quality of life in ANCA associated vasculitis. Ann. Rheum. Dis. 73, 207\u2013211 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar, C. et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68, 310\u2013317 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.lpm.2013.01.047","volume":"42","author":"GS Hoffman","year":"2013","unstructured":"Hoffman, G. S. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis? Presse Med. 42, 643\u2013650 (2013).","journal-title":"Presse Med."},{"key":"BFnrrheum2014104_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/ki.2013.24","volume":"84","author":"S Furuta","year":"2013","unstructured":"Furuta, S. & Jayne, D. R. . Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int. 84, 244\u2013249 (2013).","journal-title":"Kidney Int."},{"key":"BFnrrheum2014104_CR40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrrheum.2012.188","volume":"9","author":"R Luqmani","year":"2013","unstructured":"Luqmani, R. Maintenance of clinical remission in ANCA-associated vasculitis. Nat. Rev. Rheumatol. 9, 127\u2013132 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum2014104_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-2796.1998.00357.x","volume":"244","author":"C Franssen","year":"1998","unstructured":"Franssen, C., Gans, R., Kallenberg, C., Hageluken, C. & Hoorntje, S. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase antibodies. J. Intern. Med. 244, 209\u2013216 (1998).","journal-title":"J. Intern. Med."},{"key":"BFnrrheum2014104_CR42","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1046\/j.1523-1755.2000.00080.x","volume":"57","author":"CF Franssen","year":"2000","unstructured":"Franssen, C. F. et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int. 57, 2195\u20132206 (2000).","journal-title":"Kidney Int."},{"key":"BFnrrheum2014104_CR43","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.2215\/CJN.01020113","volume":"8","author":"AA de Joode","year":"2013","unstructured":"de Joode, A. A., Sanders, J. S. & Stegeman, C. A. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin. J. Am. Soc. Nephrol. 8, 1709\u20131717 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014104_CR44","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1002\/art.34562","volume":"64","author":"S Lionaki","year":"2012","unstructured":"Lionaki, S. et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 64, 3452\u20133462 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR45","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh, M. et al. Risk factors for relapse of antineutrophil cytoplasmic antibody associated vasculitis. Arthritis Rheum. 64, 542\u2013548 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221\u2013232 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2014104_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks, U. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417\u2013427 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2014104_CR48","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","volume":"72","author":"A Mahr","year":"2013","unstructured":"Mahr, A. et al. Revising the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann. Rheum. Dis. 72, 1003\u20131010 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/BOR.0000000000000014","volume":"26","author":"WF Pendergraft 3rd","year":"2014","unstructured":"Pendergraft, W. F. 3rd & Niles, J. L. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr. Opin. Rheumatol. 26, 42\u201349 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2014104_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/BOR.0b013e32835b4449","volume":"25","author":"J Graf","year":"2013","unstructured":"Graf, J. Rheumatic manifestations of cocaine use. Curr. Opin. Rheumatol. 25, 50\u201355 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2014104_CR51","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrrheum2014104_CR52","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.semnephrol.2013.08.006","volume":"33","author":"JC Jennette","year":"2013","unstructured":"Jennette, J. C., Xiao, H., & Hu, P. Complement in ANCA-associated vasculitis. Semin. Nephrol. 33, 557\u2013564 (2013).","journal-title":"Semin. Nephrol."},{"key":"BFnrrheum2014104_CR53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2013020143","volume":"25","author":"H Xiao","year":"2013","unstructured":"Xiao, H. et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J. Am. Soc. Nephrol. 25, 225\u2013231 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014104_CR54","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrrheum2014104_CR55","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman, G. S. et al. Wegener Granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116, 488\u2013498 (1992).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2014104_CR56","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic antibodies. N. Engl. J. Med. 349, 36\u201344 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2014104_CR57","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux, C. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Eng. J. Med. 359, 2790\u20132803 (2008).","journal-title":"N. Eng. J. Med."},{"key":"BFnrrheum2014104_CR58","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","volume":"71","author":"L Harper","year":"2012","unstructured":"Harper, L. et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis. 71, 955\u2013960 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR59","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/BOR.0000000000000009","volume":"26","author":"PA Monach","year":"2014","unstructured":"Monach, P. A. Biomarkers in vasculitis. Curr. Opin. Rheumatol. 26, 24\u201330 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2014104_CR60","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nm.2130","volume":"16","author":"EF McKinney","year":"2010","unstructured":"McKinney, E. F. et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat. Med. 16, 568\u2013591 (2010).","journal-title":"Nat. Med."},{"key":"BFnrrheum2014104_CR61","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","volume":"120","author":"CA Stegeman","year":"1994","unstructured":"Stegeman, C. A. et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 120, 12\u201317 (1994).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2014104_CR62","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","volume":"43","author":"MM Boomsma","year":"2000","unstructured":"Boomsma, M. M. et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43, 2025\u20132033 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR63","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/rheumatology\/kei272","volume":"45","author":"JS Sanders","year":"2006","unstructured":"Sanders, J. S., Huitma, M. G., Kallenberg, C. G. & Stegeman, C. A. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titers to treatment. Rheumatology (Oxford) 45, 724\u2013729 (2006).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014104_CR64","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","volume":"51","author":"G Tomasson","year":"2012","unstructured":"Tomasson, G., Grayson, P. C., Mahr, A. D., Lavalley, M. & Merkel, P. A. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis\u2014a meta-analysis. Rheumatology (Oxford) 51, 100\u2013109 (2012).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014104_CR65","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1002\/art.34584","volume":"64","author":"R Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba, R. et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 64, 3770\u20133778 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR66","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"RM Smith","year":"2012","unstructured":"Smith, R. M. et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3760\u20133769 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR67","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.lpm.2013.02.068","volume":"42","author":"L Guillevin","year":"2013","unstructured":"Guillevin, L. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients. Presse Med. 42, 679 (2013).","journal-title":"Presse Med."},{"key":"BFnrrheum2014104_CR68","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrrheum2014104_CR69","doi-asserted-by":"publisher","unstructured":"Khan, A., Lawson, C. A., Quinn, M. A., Isdale, A. H. & Green, M. J. Successful treatment of ANCA-negative Wegener's granulomatosis with rituximab. Int. J. Rheumatol. http:\/\/dx.doi.org\/10.1155\/2010\/846063 (2010).","DOI":"10.1155\/2010\/846063"},{"key":"BFnrrheum2014104_CR70","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/BOR.0000000000000015","volume":"26","author":"A Mahr","year":"2014","unstructured":"Mahr, A. et al. Eosinophilic granulomatosis with polyangiitis (Churg Strauss): evolutions in classifications, etiopathogenesis, assessment and management. Curr. Opin. Rheumatol. 26, 16\u201323 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2014104_CR71","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig, F., Gross, W. L., Herrmann, K., Bremer, J. P. & Hellmich, B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann. Intern. Med. 155, 341\u2013343 (2011).","journal-title":"Ann. Intern. Med."},{"issue":"1 Suppl. 70","key":"BFnrrheum2014104_CR72","first-page":"S62","volume":"30","author":"K Hermann","year":"2012","unstructured":"Hermann, K., Gross, W. L. & Moosig, F. Extended follow-up after stopping mepolizumab in relapsing\/refractory Churg-Strauss syndrome. Clin. Exp. Rheumatol. 30, (1 Suppl. 70), S62\u2013S65 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2014104_CR73","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrneph.2012.107","volume":"8","author":"N Wall","year":"2012","unstructured":"Wall, N. & Harper, L. Complications of long-term therapy for ANCA-associated system vasculitis. Nat. Rev. Nephrol. 8, 523\u2013533 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrrheum2014104_CR74","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.lpm.2013.01.040","volume":"42","author":"L Harper","year":"2013","unstructured":"Harper, L. Morbidity in patients with ANCA-associated vasculitis. Presse Med. 42, 612\u2013616 (2013).","journal-title":"Presse Med."},{"key":"BFnrrheum2014104_CR75","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/ard.2008.088302","volume":"68","author":"C Charlier","year":"2009","unstructured":"Charlier, C. et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann. Rheum. Dis. 68, 658\u2013663 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR76","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2215\/CJN.05610611","volume":"7","author":"JG McGregor","year":"2012","unstructured":"McGregor, J. G. et al. Glucocorticosteroids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin. J. Am. Soc. Nephrol. 7, 240\u2013247 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014104_CR77","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2215\/CJN.07300712","volume":"8","author":"R Goupil","year":"2013","unstructured":"Goupil, R. et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin. J. Am. Soc. Nephrol. 8, 416\u2013423 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014104_CR78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman, C. A., Tervaert, J. W., de Jong, P. E. & Kallenberg, C. G. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N. Engl. J. Med. 335, 16\u201320 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2014104_CR79","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s10067-013-2293-4","volume":"32","author":"E Besada","year":"2013","unstructured":"Besada, E. & Nossent, J. C. Should Pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis? Clin. Rheumatol. 32, 1677\u20131681 (2013).","journal-title":"Clin. Rheumatol."},{"issue":"1 Suppl. 75","key":"BFnrrheum2014104_CR80","first-page":"S62","volume":"31","author":"G Pugnet","year":"2013","unstructured":"Pugnet, G. et al. Progressive multifocal encephalopathy after cyclophosphamide in granulomatosis with polyangiitis (Wegener) patients: case report and review of the literature. Clin. Exp. Rheumatol. 31, (1 Suppl. 75), S62\u2013S64 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2014104_CR81","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1002\/art.34468","volume":"64","author":"ES Molloy","year":"2012","unstructured":"Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy associated with immune suppressive therapy in rheumatic diseases: involving role of biologic therapies. Arthritis Rheum. 64, 3043\u20133051 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR82","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","volume":"52","author":"E Besada","year":"2013","unstructured":"Besada, E., Koldingsnes, W. & Nossent, J. C. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single center. Rheumatology (Oxford) 52, 2041\u20132047 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014104_CR83","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/ard.2010.137216","volume":"70","author":"S van Assen","year":"2011","unstructured":"van Assen, S. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum.Dis. 70, 414\u2013422 (2011).","journal-title":"Ann. Rheum.Dis."},{"key":"BFnrrheum2014104_CR84","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1160\/TH11-09-0611","volume":"107","author":"YI Tichelaar","year":"2012","unstructured":"Tichelaar, Y. I., Kluin-Nelemans, H. J., & Meijer, K. Infections and inflammatory diseases as risk factors for venous thrombosis. A systemic review. Thromb. Haemost. 107, 827\u2013837 (2012).","journal-title":"Thromb. Haemost."},{"key":"BFnrrheum2014104_CR85","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","volume":"142","author":"PA Merkel","year":"2005","unstructured":"Merkel, P. A. et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) study. Ann. Intern. Med. 142, 620\u2013626 (2005).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2014104_CR86","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/rheumatology\/ken035","volume":"47","author":"PM Stassen","year":"2008","unstructured":"Stassen, P. M., Derks, R. P, Kallenberg, C. G. & Stegeman, C. A. Venous thromboembolism in ANCA-associated vasculitis\u2014incidence and risk factors. Rheumatology (Oxford) 47, 530\u2013534 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014104_CR87","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/ard.2008.099051","volume":"68","author":"Y Allenbach","year":"2009","unstructured":"Allenbach, Y. et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann. Rheum. Dis. 68, 564\u2013567 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR88","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/acr.20433","volume":"63","author":"R Suppiah","year":"2011","unstructured":"Suppiah, R. et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res. 63, 588\u2013596 (2011).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum2014104_CR89","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/art.24386","volume":"60","author":"M Faurschou","year":"2009","unstructured":"Faurschou, M. et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum. 60, 1187\u20131192 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR90","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1002\/art.24957","volume":"60","author":"MD Morgan","year":"2009","unstructured":"Morgan, M. D. et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum. 60, 3493\u20133500 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR91","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.berh.2012.12.004","volume":"27","author":"JW Cohen Tervaert","year":"2013","unstructured":"Cohen Tervaert, J. W. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract. Res. Clin. Rheumatol. 27, 33\u201344 (2013).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2014104_CR92","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0961203313502570","volume":"22","author":"B Parker","year":"2013","unstructured":"Parker, B. & Bruce, I. SLE and metabolic syndrome. Lupus 22, 1259\u20131266 (2013).","journal-title":"Lupus"},{"key":"BFnrrheum2014104_CR93","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/rheumatology\/keh374","volume":"43","author":"T Pankhurst","year":"2004","unstructured":"Pankhurst, T., Savage, C. O., Gordon, C. & Harper, L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford) 43, 1532\u20131535 (2004).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014104_CR94","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/rheumatology\/kep009","volume":"48","author":"M Faurschou","year":"2009","unstructured":"Faurschou, M. et al. Cancer preceding Wegener's granulomatosis: a case\u2013control study. Rheumatology (Oxford) 48, 421\u2013424 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014104_CR95","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","volume":"124","author":"C Talar-Williams","year":"1996","unstructured":"Talar-Williams, C. et al. Cyclophosphamide-induced cystitits and bladder cancer in patients with Wegener's granulomatosis. Ann. Intern. Med. 124, 477\u2013484 (1996).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2014104_CR96","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.V95842","volume":"9","author":"KW Westman","year":"1998","unstructured":"Westman, K. W., Bygren, P. G., Olsson, H., Ranstam, J. & Wieslander, J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J. Am. Soc. Nephrol. 9, 842\u2013852 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014104_CR97","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/art.30296","volume":"63","author":"G Le Guenno","year":"2011","unstructured":"Le Guenno, G. et al. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum. 63, 1435\u20131445 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR98","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1136\/ard.2010.145250","volume":"70","author":"C Heijl","year":"2011","unstructured":"Heijl, C. et al. Incidence of malignancy in patients treated for antineutrophil cytoplasmic antibody-associated vasculitis: follow-up data from European vasculitis study group clinical trials. Ann. Rheum. Dis. 70, 1415\u20131421 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014104_CR99","doi-asserted-by":"crossref","unstructured":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351\u2013361 (2005).","DOI":"10.1056\/NEJMoa041884"},{"key":"BFnrrheum2014104_CR100","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/art.21869","volume":"54","author":"JH Stone","year":"2006","unstructured":"Stone, J. H. et al. Solid malignancies among patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 54, 1608\u20131618 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR101","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1002\/art.30394","volume":"63","author":"F Silva","year":"2011","unstructured":"Silva, F. et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term follow up of a multicenter longitudinal cohort. Arthritis Rheum. 63, 2495\u20132503 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014104_CR102","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.berh.2012.12.003","volume":"27","author":"A Mahr","year":"2013","unstructured":"Mahr, A. Heijl, C., Le Guenno, G. & Faurschou, M. ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract. Res. Clin. Rheumatol. 27, 45\u201356 (2013).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2014104_CR103","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/BOR.0000000000000049","volume":"26","author":"CG Kallenberg","year":"2014","unstructured":"Kallenberg, C. G. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis? Curr. Opin. Rheumatol. 26, 292\u2013298 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2014104_CR104","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.lpm.2013.02.067","volume":"42","author":"R Jones","year":"2013","unstructured":"Jones, R. et al. A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: \u201cMYCYC\u201d. Presse Med. 42, 678\u2013679 (2013).","journal-title":"Presse Med."},{"key":"BFnrrheum2014104_CR105","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/ki.2013.131","volume":"84","author":"M Walsh","year":"2013","unstructured":"Walsh, M. et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 84, 397\u2013402 (2013).","journal-title":"Kidney Int."},{"key":"BFnrrheum2014104_CR106","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra, T. F. et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304, 2381\u20132388 (2010).","journal-title":"JAMA"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.104","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:33:59Z","timestamp":1684470839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2014.104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,1]]},"references-count":106,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["BFnrrheum2014104"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2014.104","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,1]]},"assertion":[{"value":"1 July 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}